HC Wainwright Reiterates Buy Rating for Genmab A/S (NASDAQ:GMAB)

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note published on Tuesday morning, Benzinga reports. The firm currently has a $50.00 price objective on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q3 2024 earnings at $0.35 EPS, Q4 2024 earnings at $0.41 EPS and FY2024 earnings at $1.39 EPS.

A number of other equities analysts also recently issued reports on the company. JPMorgan Chase & Co. reiterated a neutral rating on shares of Genmab A/S in a report on Tuesday, August 20th. Royal Bank of Canada upgraded shares of Genmab A/S from a sector perform rating to an outperform rating in a research note on Monday, July 15th. BTIG Research boosted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a buy rating in a research note on Thursday, June 27th. Finally, Truist Financial raised their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the company a buy rating in a research note on Tuesday, June 4th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S presently has an average rating of Hold and an average target price of $49.50.

Genmab A/S Trading Up 0.4 %

Shares of GMAB opened at $27.81 on Tuesday. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $39.53. The firm’s 50-day moving average price is $26.78 and its 200-day moving average price is $28.15. The firm has a market capitalization of $18.39 billion, a price-to-earnings ratio of 23.18, a PEG ratio of 1.01 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a net margin of 30.74% and a return on equity of 18.90%. The firm had revenue of $779.50 million for the quarter, compared to the consensus estimate of $734.60 million. On average, research analysts forecast that Genmab A/S will post 1.13 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently bought and sold shares of GMAB. International Assets Investment Management LLC purchased a new stake in shares of Genmab A/S during the fourth quarter valued at approximately $393,000. Benjamin F. Edwards & Company Inc. purchased a new stake in Genmab A/S during the 4th quarter valued at $216,000. M&T Bank Corp increased its holdings in shares of Genmab A/S by 87.8% in the 4th quarter. M&T Bank Corp now owns 15,432 shares of the company’s stock worth $492,000 after purchasing an additional 7,213 shares in the last quarter. Vestmark Advisory Solutions Inc. raised its stake in shares of Genmab A/S by 28.5% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 35,656 shares of the company’s stock worth $1,135,000 after purchasing an additional 7,905 shares during the last quarter. Finally, Principal Securities Inc. purchased a new position in shares of Genmab A/S in the fourth quarter worth $77,000. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.